dc.contributor.author | Haddad, R | |
dc.contributor.author | Cohen, EEW | |
dc.contributor.author | Venkatachalam, M | |
dc.contributor.author | Young, K | |
dc.contributor.author | Singh, P | |
dc.contributor.author | Shaw, JW | |
dc.contributor.author | Korytowsky, B | |
dc.contributor.author | Abraham, P | |
dc.contributor.author | Harrington, KJ | |
dc.date.accessioned | 2020-03-24T12:34:18Z | |
dc.date.issued | 2020-05-03 | |
dc.identifier.citation | Journal of medical economics, 2020, 23 (5), pp. 442 - 447 | |
dc.identifier.issn | 1369-6998 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3550 | |
dc.identifier.eissn | 1941-837X | |
dc.identifier.doi | 10.1080/13696998.2020.1715414 | |
dc.description.abstract | Aim: To assess the cost-effectiveness of nivolumab monotherapy for recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the US.Methods: We constructed a cohort-based partitioned survival model for three health states (progression-free, progressed disease, and death). Using overall survival and progression-free survival data from the nivolumab and investigator's choice (IC) arms of the CheckMate 141 study, the proportion of patients in each health state was estimated by parametric modeling over a 25-year period. Cost, utility, adverse event, and disease management data inputs were obtained from relevant literature and applied to patients in each health state. A scenario analysis was conducted assuming increased uptake of subsequent immunotherapies. A one-way deterministic sensitivity analysis assessed the impact of variation in multiple parameters. A probabilistic sensitivity analysis in which probabilistic distributions were applied to each input during 1,000 model iterations was also conducted.Results: Total costs incurred were higher with nivolumab ($101,552) than with IC ($38,067). Nivolumab was associated with a higher number of life-years (LY; 1.21) and quality-adjusted life-years (QALYs; 0.89), compared with IC (0.68 and 0.42, respectively). The incremental cost-effectiveness ratio for nivolumab compared with IC was $134,438 per QALY, and this remained qualitatively similar when increased uptake of subsequent immunotherapies was assumed ($129,603 per QALY). Sensitivity analyses supported these findings.Conclusions: These results suggest that, at a willingness-to-pay threshold of $150,000 per QALY, nivolumab is a cost-effective option for therapy of SCCHN in the US. | |
dc.format | Print-Electronic | |
dc.format.extent | 442 - 447 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | TAYLOR & FRANCIS LTD | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. | |
dc.type | Journal Article | |
rioxxterms.versionofrecord | 10.1080/13696998.2020.1715414 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2020-05 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Journal of medical economics | |
pubs.issue | 5 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
pubs.publication-status | Published | |
pubs.volume | 23 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Targeted Therapy | |
dc.contributor.icrauthor | Harrington, Kevin | |